Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.44 |
| ▸ | CDK4 | P11802 | 5/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249226 | 0.83 | MAPT (0.45) | CYP3A4HRH3 | |
| SCHEMBL20255191 | 0.82 | HRH4 (0.43) | HRH4CDK4CDK6CYP3A4HRH3 | |
| SCHEMBL20249098 | 0.82 | MAPT (0.46) | CYP3A4HRH3 | |
| SCHEMBL20255284 | 0.81 | HRH4 (0.45) | HRH4CDK4CDK6ROCK2ROCK1 | |
| SCHEMBL20224120 | 0.79 | CYP3A4 (0.47) | CDK4CDK6CYP3A4HRH3 | |
| SCHEMBL22601459 | 0.79 | MAPT (0.50) | HRH3 | |
| SCHEMBL20249271 | 0.79 | HRH4 (0.32) | HRH4CDK4CDK6CYP3A4 | |
| SCHEMBL20037607 | 0.79 | HRH4 (0.46) | HRH4CDK4CDK6ROCK2ROCK1 | |
| SCHEMBL20038446 | 0.79 | HRH4 (0.43) | HRH4CDK4CDK6ROCK2ROCK1 | |
| SCHEMBL25650084 | 0.79 | CDK4 (0.50) | HRH4CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885CDK4 1/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.